142 Results for "

human PD-1

" in MedChemExpress (MCE) Product Catalog:
Products (142)

142 Results for "human PD-1" in MCE Product Catalog:

35
35 Publications Verification
Cat. No.: HY-136927
CAS No.: 129425-81-6
Purity:  99.81%
Target:  

STING

Research Areas:  

Inflammation/Immunology Cancer

MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-19745
CAS No.: 1675203-84-5
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-19745B
CAS No.: 2089334-95-0
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-P9903
CAS No.: 946414-94-4
Synonyms: BMS-936558; ONO-4538; MDX-1106

Target:  

PD-1/PD-L1

Research Areas:  

Infection Cancer

Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P9919
CAS No.: 1428935-60-7
Synonyms: MEDI 4736

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P9919A
CAS No.: 1428935-60-7
Synonyms: MEDI 4736 (anti-PD-L1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P81169A
Synonyms: Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_human; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2.

Host:  

Mouse

Application:  

WB, IHC-P, ICC/IF, FC

Reactivity:  

Human

loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P7395
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PDCD1; Systemic Lupus Erythematosus Susceptibility 2; Prev. SLEB2; HPD-1; PD1; Programmed Cell Death 1 Protein; Programmed Cell Death Protein 1; CD279 Antigen; CD279; ADMIO4; HSLE1; AIMTBS; PD-1; HPD-L; Programmed Cell Death 1; Protein PD-1
Species:  
Source:  
CHO
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99100
CAS No.: 2556646-63-8
Synonyms: CTL-002

Research Areas:  

Cancer

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P7396
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PDCD1; Systemic Lupus Erythematosus Susceptibility 2; Prev. SLEB2; HPD-1; PD1; Programmed Cell Death 1 Protein; Programmed Cell Death Protein 1; CD279 Antigen; CD279; ADMIO4; HSLE1; AIMTBS; PD-1; HPD-L; Programmed Cell Death 1; Protein PD-1
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P70577
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuclein; Synuclein, Alpha (Non A4 Component Of Amyloid Precursor); Α-Synuclein; Synuclein Alpha; Non A4 Component Of Amyloid Precursor
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P73344A
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.;≥ 90%, as determined by HPLC.
Synonyms: PDCD1; Systemic Lupus Erythematosus Susceptibility 2; Prev. SLEB2; HPD-1; PD1; Programmed Cell Death 1 Protein; Programmed Cell Death Protein 1; CD279 Antigen; CD279; ADMIO4; HSLE1; AIMTBS; PD-1; HPD-L; Programmed Cell Death 1; Protein PD-1
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P71327
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-160041
CAS No.: 1390628-22-4
Synonyms: NOX-A12
Target:  

CXCR

Research Areas:  

Cancer

Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-160041A
Synonyms: NOX-A12 sodium
Target:  

CXCR

Research Areas:  

Cancer

Olaptesed pegol (NOX-A12) sodium is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0819
CAS No.: 89412-79-3
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .
loading...
    loading...
Cat. No.: HY-P99115
CAS No.: 2102192-68-5
Synonyms: ASC 22; KN 035

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P10375
CAS No.: 1629665-96-8
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 .
loading...
    loading...
Cat. No.: HY-P99457
CAS No.: 2148321-77-9
Synonyms: AGEN2034

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .
loading...
    loading...